JSJeffrey F. Scott

Jeffrey F. Scott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey F. Scott has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Kord Honda

    Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio

    4 shared publications
  • Meg R. Gerstenblith

    Department of Dermatology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio

    4 shared publications
  • Jeremy S. Bordeaux

    All authors are affiliated with the Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio

    3 shared publications
  • Ritva Vyas

    Department of Dermatology University Hospitals Cleveland Medical Center

    3 shared publications
  • Cheryl L. Thompson

    Department of Family Medicine and Community Health, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio

    2 shared publications
  • Jeremy S. Bordeaux

    Department of Dermatology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio

    2 shared publications

Latest Publications

  • Evaluating publication bias for clinical trials supporting new dermatologic drug approvals from 2003 to 2018

    by Sairekha Ravichandran, Kathleen M. Mulligan, Harib H. Ezaldein, Jeffrey F. Scott

    The degree of publication bias and impact of the Food and Drug Administration Amendments Act (FDAAA) of 2007, which aimed to improve clinical trial transparency, has yet to be examined for recent dermatologic drugs. The objective of our study was to estimate the degree of publication bias for clinical trials supporting FDA approval of new dermatologic drugs. This retrospective cohort study examined all phase II and III efficacy trials supporting approval of new dermatologic drugs from 2003 to 2018. FDA drug approval documents were reviewed for supportive clinical trial information, and publications were matched using PubMed and Google Scholar searches. Ratios of relative risks (RRR) comparing positive versus non-positive trials before and after FDAAA enactment served to estimate publication bias. We found that the likelihood of publishing positive versus non-positive drug trials in dermatology was unchanged before and after FDAAA enactment (RRR 0.87, 95% CI 0.37–2.08), as was the likelihood of publishing without misleading interpretation (RRR 1.51, 95% CI 0.22–10.50). There was no measurable publication bias for efficacy trials supporting new drug approvals in dermatology over the past 15 years. Fewer pre-FDAAA trials (n = 21) compared to post-FDAAA trials (n = 106) met inclusion criteria. Though not analyzed in this study, safety and secondary efficacy results are other potential sources for publication bias.

  • Cosmetic dermatologic surgery fellowship websites and social media presence: Opportunities for improved applicant recruitment

    by Kathleen M. Mulligan, David X. Zheng, Christopher R. Cullison, Christina Wong, Jeffrey F. Scott

    Introduction The American Society for Dermatologic Surgery (ASDS) established a cosmetic dermatologic surgery fellowship in 2013. Programs often outline details of fellowships on their websites to help prospective applicants make informed decisions. Our primary goal was to evaluate the content quality of online information for all ASDS-accredited cosmetic dermatologic surgery fellowships on program websites and the ASDS website. Our secondary goal was to describe program activity on social media platforms as another avenue for applicant recruitment. Methods Program websites were assessed using an aggregate score from twenty-one standardized content quality variables. Social media activity on Facebook and Instagram from January 6 2021, to March 6, 2021, was categorized. Results Among 24 cosmetic dermatologic surgery fellowship programs, 23 had websites. Basic information was provided across most websites or the ASDS website (eg, address, 95.8%), but more qualitative variables like research opportunities or didactic schedule were not consistently reported. Most programs had highly active social media accounts (91.7% on Facebook and 79.2% on Instagram). Conclusion There is a gap of information availability between the ASDS website and individual cosmetic dermatologic surgery fellowship websites. Increasing information availability may enhance the applicant recruitment process and serve as a low-cost intervention to ensure optimal fit.


  • Open Access

    Factors associated with leaving against medical advice among patients hospitalized for dermatologic conditions

    by Raghav Tripathi, Rishabh S. Mazmudar, Jeremy S. Bordeaux, Jeffrey F. Scott


  • A Conceptual Approach to Designing Transposition Flaps

    by Jeffrey F. Scott, Jeremy S. Bordeaux

    BACKGROUND: The large number of transposition flap geometries available for cutaneous reconstruction often makes the design of these flaps difficult for less experienced dermatologic surgeons. OBJECTIVE: To present a conceptual approach to designing transposition flaps based on 2 elementary angles. MATERIALS AND METHODS: First, a simplified framework for designing transposition flaps is presented, based on: (1) the takeoff point of the flap, (2) the angle between the primary limb and the primary defect (Angle A), and (3) the angle between the secondary limb and the primary limb (Angle B). Next, a comprehensive literature review highlights applications of the above conceptual approach in the design of z-plasties and single-lobed and multi-lobed transposition flaps. RESULTS: Different types of transposition flaps all share the same key design elements, and modifications to Angle A and Angle B predict flap biomechanics. CONCLUSION: The design of transposition flaps can be simplified by understanding how 2 elementary angles influence the geometry and biomechanics of various transposition flaps.


  • A granny sliding knot for high-tension closures

    by Jeffrey F. Scott, Mona Ascha, Whitney Pollard, Jeremy S. Bordeaux


  • Open Access

    United States Food and Drug Administration’s 510(k) Pathway: Drawing Implications from the Approvals of Brachytherapy Devices

    by Sophie Wang, Albert Manudhane, Harib H. Ezaldein, Jeffrey F. Scott

    Innovations in cancer treatment coupled with an increasing number of cancer patients have led to the growth of brachytherapy devices. The objective of this study is to characterize the development and safety of brachytherapy devices marketed in the United States (US) over the last 15 years. We reviewed records from a public US Food and Drug Administration (FDA) database detailing premarket approval of brachytherapy devices. All 510(k) submissions approved between January 1, 2000 and October 31, 2018 were examined. To assess the safety of these devices, we searched the manufacturer and user facility device experience (MAUDE) database for related adverse events. Twenty-two brachytherapy devices received 510(k) premarket approval, with the first device approved in 2005. Of the 22 devices, 20 (91%) were marketed with specific indications. The most common indications include treatment of skin cancers and keloids (n=7), breast cancer (n=4), and gynecologic/rectal cancers (n=2). A review of the MAUDE database revealed 64 reports of adverse events associated with brachytherapy devices. Common adverse effects include poor device design, use error, and device malfunction that led to the delivery of an inaccurate dose of radiation. Although there are some single-center, short-term studies demonstrating adequate local control and satisfactory cosmesis with brachytherapy, data on long-term outcomes are lacking. Further research is warranted to define appropriate practice guidelines for brachytherapy devices in the treatment of various malignancies.


  • Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014

    by Jeffrey F. Scott, Ruzica Z. Conic, Cheryl L. Thompson, Meg R. Gerstenblith, Jeremy S. Bordeaux


  • Open Access

    Genitourinary Melanoma

    by Pooja H. Rambhia, Jeffrey F. Scott, Ritva Vyas, Meg R. Gerstenblith, Md

    Noncutaneous melanoma, edited by Drs. Scott and Gerstenblith, integrates the expertise of a multidisciplinary group of clinicians and investigators to help shed light on recent advances in the understanding of noncutaneous melanomas. The authors skillfully present a comprehensive review of uveal melanoma, the most common type of ocular melanoma, as well as nasopharyngeal, genitourinary, and anorectal melanoma, and finally melanoma of unknown primary. This book will be highly valuable to clinicians caring for patients with noncutaneous melanoma who desire a review of the current literature regarding these entities. As the diagnostic and therapeutic approaches to these patients are continually evolving, it is imperative for clinicians to stay well versed on new advances gleaned from the primary literature. This book addresses each topic in sophisticated detail, and it will be a valuable resource for clinicians and investigators to assist in patient care and guide further research.


  • Primary bilateral uveal melanoma: a population‐based study and systematic review

    by Jeffrey F Scott, Ritva Vyas, Jessica Galvin, Erica Gotow, Lori Fiessinger, Adam T Gerstenblith, Meg R Gerstenblith

    Importance: Primary bilateral uveal melanoma (UM) is a rare and incompletely described entity. It is not known how these patients compare to those with unilateral UM.Background: We sought to comprehensively characterize and compare patients with primary bilateral and unilateral UM.Design: Retrospective, population‐based and systematic review.Participants: Patients with bilateral (n = 52) and unilateral UM (n = 8915).Methods: We analysed cases of primary bilateral UM from three data sources: (i) the University Hospitals Cleveland Medical Center pathology database from 1996 to 2016 (n = 1); (ii) the Surveillance, Epidemiology and End‐Results (SEER)‐18 database from 1973 to 2013 (n = 5) and (iii) a systematic review of the English language literature (n = 46). Cases of unilateral UM were obtained from the SEER‐18 database from 1973 to 2013 for comparison (n = 8915).Main Outcome Measures: Demographics, clinicopathological characteristics, treatments and survival.Results: There were no differences in sex, race, mean age at diagnosis, site of uveal involvement, metastases at diagnosis, or treatment among patients with bilateral as compared to unilateral UM. Additionally, there were no clinicopathological differences between the two UMs in each patient with bilateral disease. Overall survival did not differ between unilateral and bilateral UM patients, or between bilateral UM patients who presented with, or subsequently developed, bilateral disease.Conclusions and Relevance: Bilateral and unilateral UM patients share similar demographics, clinicopathological characteristics, treatments and prognoses. Moreover, the development of bilateral disease does not portend a poorer prognosis and patients should be treated similarly to those with unilateral disease.